Kyoto Univ. Begins Trial to Treat Preceding Stage of Cervical Cancer

Society Lifestyle

Kyoto, June 6 (Jiji Press)--A research team of Kyoto University said Thursday that it has started a trial to administer a treatment to patients with cervical intraepithelial neoplasm, the preceding stage of cervical cancer.

The team aims to commercialize the treatment in three years if its safety and effectiveness are confirmed.

Infection with the human papillomavirus, or HPV, is the main cause for cervical intraepithelial neoplasm, which could lead to cervical cancer.

The trial started on the heels of the discovery by Masatoshi Hagiwara, a professor at the Japanese university, of a low-molecular compound, named FIT-039, that works to prevent the proliferation of HPV.

The team started in April to administer the compound to healthy women in menopause only once to check any side effects. The team will then assess the effect of the therapy by giving it to patients with mild to moderate cervical intraepithelial neoplasm for two weeks.

[Copyright The Jiji Press, Ltd.]

Jiji Press